Juventas Therapeutics

Early Stage Partners participated in the Series A early stage venture capital investment in the therapeutics company Juventas Therapeutics, which is developing Stromal Derived Factor, or SDF-1, to repair damage to heart and other tissue. SDF-1 is a naturally occurring universal recruiter of a body's own stem cells to areas of damaged tissue. Juventas is demonstrating that the application of SDF-1 to injured tissue, long after the body's own repair mechanism has ceased producing SDF-1, can regenerate tissue by promoting new blood vessel formation and preventing ongoing cell death.

Recent Juventas News

 Juventas Founder Marc Penn Explains Juventas' Therapy on Television News

Juventas Cleared to Being Phase II Clinical Trials For Critical Limb Ischemia

Juventas Successfully Completes Phase I Trial Of Its Lead Compound

Find Out More About ESP